Protara Therapeutics, Inc.: management transactions · United States · SEC (Form 4)

About Protara Therapeutics, Inc.

Protara Therapeutics, Inc. is a U.S.-based clinical-stage biotechnology company listed on the Nasdaq market in the United States under ticker TARA. From an equity analyst’s perspective, Protara should be viewed as a development-stage specialty pharma/biotech name rather than a commercial company: its investment case is driven primarily by clinical readouts, regulatory progress, and financing capacity, not by recurring product revenue. The company’s profile is typical of Nasdaq-listed biotechs where valuation is highly sensitive to trial data and FDA interactions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai)) The company is headquartered in New York City, New York. Its strategy is centered on two lead programs. The first is TARA-002, an intravesical therapy being developed for non-muscle invasive bladder cancer (NMIBC), including both BCG-unresponsive and BCG-naïve settings. The second is intravenous choline chloride, being studied for patients dependent on parenteral support. This focused pipeline gives Protara a relatively concentrated but potentially value-creating clinical portfolio, with the company’s near- to mid-term narrative tied to advancing these programs through late-stage development and, ultimately, toward potential registration. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai)) Historically, Protara has been built as a biotechnology platform focused on differentiated assets in high-need indications. Rather than competing on breadth, it competes on specificity: it targets disease areas where existing treatment options remain limited or suboptimal, and where a well-tolerated therapy could gain meaningful clinical adoption if efficacy is confirmed. In bladder cancer, the competitive environment is crowded and scientifically demanding, so differentiation will depend on efficacy, safety, and ease of administration. In rare diseases such as lymphatic malformations, the opportunity is attractive because unmet need is high, but commercial success will depend on the strength of clinical evidence and the ability to translate early promise into regulatory momentum. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai)) Recent milestones have been an important part of the story. In 2025 and 2026, Protara reported ongoing clinical progress across its pipeline, including updates for TARA-002 in NMIBC and lymphatic malformations, along with FDA designations that support the program’s development path. The company also strengthened its balance sheet through an equity financing in late 2025, improving cash visibility and reducing near-term funding pressure. For investors, the name remains a classic clinical-stage Nasdaq biotechnology story in the United States: promising science, meaningful upside optionality, but also binary trial and regulatory risk. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1359931/000121390026025432/ea028040401ex99-1.htm?utm_source=openai))